

EXHIBIT 1

AUSTRALIA

Patents Act 1990

IN THE MATTER OF
US Patent Application No. 09/446,109
by The University of Queensland

EXHIBIT SMT-1

This is Exhibit SMT-1 referred to in the Statutory Declaration by Stephen Maxwell Taylor
dated 12 MAY 2004

Before me:

Joni Lux



A person empowered to witness Statutory
Declarations under the laws of the Queensland,
Commonwealth of Australia

CURRICULUM VITAE

Steve M. Taylor

Personal:

Place of birth: England
Citizenship: British/Australian

Education:

B.Sc. (Hons.1), 1971	University of Sydney, Australia
Ph.D. (Pharmacology), 1978	University of Sydney, Australia

Post-Doctoral Experience:

1978-1982	Research Associate, Dept. of Pharmacology, School of Medicine, Oregon Health Sciences University, Portland, OR, U.S.A.
1982-1983	Research Fellow, Pulmonary Research Laboratory, Dept. of Medicine, St. Paul's Hospital, Vancouver, B.C., Canada
1983-1988	Research Assistant Professor, Dept. of Veterinary and Comparative Anatomy, Physiology and Pharmacology, & Dept. of Veterinary Microbiology & Pathology, Washington State University, Pullman, WA, U.S.A.
1988-1990	Senior Scientist, Immunetech Pharmaceuticals, San Diego, CA, U.S.A.
1990-1993	Lecturer in Pharmacology, University of Queensland Brisbane, Qld 4072, Australia
1994-1999	Senior Lecturer, University of Queensland Brisbane, Qld 4072, Australia
11/1999	Director of Pharmacology, <i>Promics</i> Pty Ltd
2000-	Reader in Pharmacology, Univ. Qld
2001-	Chief Scientist, Promics P/L

Membership in Professional Societies:

American Society for Pharmacology and Experimental Therapeutics
Leukocyte Society
Australian Society For Clinical and Experimental Pharmacology and
Toxicology
Australian Society for Cytokines, Inflammation and Leukocytes

Teaching:

1970-75 Demonstrator in Pharmacology, University of Sydney
1980-81 Visiting Lecturer in Pharmacology, Oregon Health
Sciences University, Portland, Oregon, USA
1983-84 Visiting Lecturer in Pharmacology, Department of
Pharmacology, College of Veterinary Medicine,
Washington State University, Pullman, WA, USA
1990- Lecturer/Senior Lecturer/Reader in Pharmacology,
University of Queensland

PUBLICATIONS

1. Malor, R., Griffin, C.J., and Taylor, S.M. Innervation of the blood vessels in the guinea pig atria. *Cardiovasc. Res.* 7: 95-104, 1973.
2. Malor, R., Taylor, S.M., Chesher, G.B. and Griffin, C.J. The intramural ganglia and chromaffin cells in guinea pig atria: an ultrastructural study. *Cardiovasc. Res.* 8: 731-744, 1974.
3. Taylor, S.M., Rodgers, R.M., Lynn, R.K., and Gerber, N. The seminal excretion, plasma half-life, tissue distribution and metabolism of naltrexone in the rabbit. *J. Pharmacol. Exp. Ther.* 213: 289-299, 1980.
4. Dickinson, R.G., Taylor, S.M., Kaufman, S.N., Rodgers, R.M., Gerber, N., and Baughman, W.J. Nonlinear elimination and choleretic effect of valproic acid in the monkey. *J. Pharmacol. Exp. Ther.* 213: 38-48, 1980.
5. Rogers, R.M., Taylor, S.M., Dickinson, R.G., Ilias, A.M., Lynn, R.K., and Gerber, N. Metabolism and choleretic effect of naltrexone in the isolated perfused rat liver. *Drug. Metab. Dispos.* 8: 390-396, 1980.
6. Koga, Y., Downes, H., and Taylor, S.M. Direct and indirect actions of dopamine on tracheal smooth muscle. *Nauyn Schmiedeberg's Arch. Pharmacol.* 315: 15-20, 1980.

7. Ilias, A.M., and Taylor, S.M. The seminal excretion, blood elimination, tissue distribution and metabolism of L-alpha-acetylmethadol in the rabbit. *Res. Commun. Subst. Abuse* 3: 443-452, 1982.
8. Downes, H., and Taylor, S.M. A potent, structurally specific stimulant action of procaine in bullfrog lung. *Comp. Biochem. Physiol.* 72(C): 39-43, 1982.
9. Taylor, S.M., and Downes, H. Bronchodilator mechanisms in bullfrog lung: differences in response to isoproterenol, theophylline and papaverine. *J. Pharmacol. Exp. Ther.* 223: 359-367, 1982.
10. Downes, H., and Taylor, S.M. Distinctive pharmacological profile of a nonadrenergic inhibitory system in bullfrog lung. *Br. J. Pharmacol.* 78: 339-351, 1983.
11. Taylor, S.M., Downes, H., Hirshman, C.A., Peters, J.E., and Leon, D. Pulmonary uptake of mannitol as an index of changes in lung epithelial permeability. *J. Appl. Physiol.* 55: 614-618, 1983.
12. Taylor, S.M., and Downes, H. Effect of stimulation of nonadrenergic inhibitory nerves on cyclic nucleotide levels in bullfrog lung. *Comp. Biochem. Physiol.* 77(C): 311-313, 1984.
13. Taylor, S.M., Pare, P.D., and Schellenberg, R.R. Cholinergic and nonadrenergic mechanisms in human and guinea pig airways. *J. Appl. Physiol.* 56: 958-965, 1984.
14. Armour, C.L., Lazar, N.M., Schellenberg, R.R., Taylor, S.M., Chan, N., Hogg, J.C., and Pare, P.D. A comparison of *in vivo* and *in vitro* human airway reactivity to histamine. *Am. Rev. Respir. Dis.* 129: 907-910, 1984.
15. Taylor, S.M., Bennett, G., Abbott, L.C., and Finnell, R.H. Anticonvulsant sensitivity in the mutant mouse, quaking. *European J. Pharmacol.* 118: 163-170, 1985.
16. Taylor, S.M., Pare, P.D., Armour, C.L., Hogg, J.C. and Schellenberg, R.R. Airway reactivity in Chronic Obstructive Pulmonary disease: Failure of *in vivo* methacholine responsiveness to correlate with cholinergic, adrenergic, or non-adrenergic responses *in vitro*. *Am. Rev. Resp. Dis.* 132: 30-35, 1985.
17. Taylor, S.M., Liggitt, H.D., Laegreid, W.W., Silflow, R., and Leid, R.W. Arachidonic acid metabolism in bovine alveolar macrophages. Effect of calcium ionophore on lipoxygenase products. *Inflammation.* 10: 157-165, 1986.
18. Downes, H., Edelstein, R.A., and Taylor, S.M. Mechanisms of intrinsic tone in bullfrog lung; relaxant effects of indomethacin, ouabain, and potassium. *Brit. J. Pharmacol.* 87: 579-586, 1986.
19. Leid, R.W., Taylor, S.M., Heidel, J.R., Laegreid, W.W., Liggitt, H.D., Potter, K.A., Silflow, R., and Breeze, R.G. Arachidonate metabolites from bovine alveolar and peripheral blood neutrophils. *Proceedings 14th World Congress of Diseases of Cattle.* 1: 549-554, 1986
20. Husain, A., Pajka, S.F., Taylor, S.M., and Speth, R.C. Biological actions of monoiodo-angiotensin II. *J. Pharmacol. Exp. Ther.* 239: 71-77, 1986.

21. Finnell, R.H., Mohl, V.R., Bennett, G.B., and Taylor, S.M. The role of epoxidation in carbamazepine-induced teratogenesis. *Teratogenesis Mutagenesis and Carcinogenesis*. **6**: 393-401, 1986.
22. Lyles, W.C., Taylor, S.M., Finnell, R.H., Lai, H., and Nathanson, N. Decreased muscarinic acetylcholine receptor number in the CNS of the tottering (tg/tg) mouse. *J. Neurochem.* **46**: 977-982, 1986.
23. Willow, M., Taylor, S.M., Catterall, W.A., and Finnell, R.H. Down regulation of sodium channels in nerve terminals of spontaneously epileptic mice. *Cellular and Molecular Neurobiology*. **6**: 213-220, 1986.
24. Taylor, S.M., and Finnell, R.H. Effect of quinidine and tetrodotoxin on non-adrenergic neurones in guinea-pig trachealis muscle. *Comp. Biochem. Physiol.* **86C**: 11-15, 1987.
25. Pare, P.D., Armour, C.A., Taylor, S.M., Mullen, B., Moreno, R., Hogg, J.C. and Schellenberg, R.R. Airway hyperreactivity in COPD. Cause or effect, an *in vitro-in vivo* comparison. *Chest* **91**: 41S-44S, 1987.
26. Taylor, S.M., Laegreid, W.W., Heidel, J., Straub, K., Liggitt, H.D., Silflow, R., Breeze, R.G., and Leid, R.W. Arachidonic and eicosapentaenoic acid metabolism in bovine peripheral blood neutrophils and platelets: effect of calcium ionophore. *J. Leukocyte Biol.* **42**: 253-262, 1987.
27. Finnell, R.H., Shields, H., Taylor, S.M., and Chernoff, G.F.. Strain differences in phenobarbital-induced teratogenesis in mice. *Teratology*. **35**: 177-185, 1987.
28. Laegreid, W.W., Taylor, S.M., Liggitt, H.D., Straub, K., Silflow, R., Breeze, R.G., and Leid, R.W. Production of lipoxygenase metabolites of eicosapentaenoic acid by bovine alveolar macrophages *in vitro*. *Inflammation* **12**: 503-514, 1988.
29. Finnell, R.H., Abbott, L.C., and Taylor, S.M. The fetal hydantoin syndrome: answers from a mouse model. *Reproductive Toxicology*. **3**: 127-133, 1989.
30. Laegreid, W.W., Taylor, S.M., Englen, M.D., Silflow, R.M., Liggitt, H.D., and Leid, R.W. Stimulus-selective production of cyclo-oxygenase and lipoxygenase metabolites of arachidonic acid by bovine alveolar macrophages. *Inflammation* **13**: 233-244, 1989.
31. Laegreid, W.W., Liggitt, H.D., Silflow, R.M., Evermann, J.R., Taylor, S.M., and Leid, R.W. Reversal of virus-induced alveolar macrophage bactericidal dysfunction by cyclo-oxygenase inhibition *in vitro*. *J. Leukocyte Biol.* **45**: 283-292, 1989.
32. Laegreid, W.W., Taylor, S.M., Liggitt, H.D., Evermann, J., Silflow, R and R.W. Leid. Virus-induced enhancement of arachidonate metabolism by bovine alveolar macrophages *in vitro*. *J. Leukocyte Biol.* **45**: 293-300, 1989.
33. Englen, M.D., Taylor, S.M., Laegreid, W.W., Liggitt, H.D., Silflow, R.M. and Leid, R.W. Stimulation of arachidonic acid metabolism in silica-exposed alveolar macrophages. *Exp. Lung Research*. **15**: 511-526, 1989.
34. Heidel, J.R., Taylor, S.M., Laegreid, W.W., Silflow, R.M., Liggitt, H.D., and Leid, R.W. Characterisation of arachidonic acid metabolism, superoxide production, and

bacterial killing in bovine circulating neutrophils and elicited alveolar neutrophils. *J. Leukocyte Biol.* 46: 41-50, 1989

35. Heidel, J.R., Taylor, S.M., Laegreid, W.W., Silflow, R.M., Liggitt, H.D. and Leid, R.W. *In vivo* chemotaxis of bovine neutrophils by 5-lipoxygenase metabolites of arachidonic and eicosapentaenoic acid. *Am. J. Pathology.* 134: 671-676, 1989.
36. Silflow, R.M., Foreyt, W.J., Taylor, S.M., Laegreid, W.W., Liggitt, H.D. and R.W. Leid. Comparison of pulmonary defense mechanisms in bighorn and domestic sheep. *J. Wildlife Diseases* 25: 514-520, 1989
37. Heidel, J.R., Sassenfeld, C.R., Maliszewski, R.M. Silflow, Baker, P.E, Taylor, S.M. and R.W. Leid. Functional studies of bovine alveolar neutrophils elicited with recombinant bovine IL-1 β . *J. Immunol.* 144: 1037-1041, 1990
38. Taylor, S.M., Laegreid, W.W., Englen, M.D., Dani, G., Silflow, R., Liggitt, H.D. and R.W. Leid. Influence of extracellular calcium on arachidonic acid metabolism in alveolar macrophages. *J. Leukocyte Biol.* 48: 502-511, 1990
39. Englen, M.D., Taylor, S.M., Laegreid, W.W., Silflow, R., Banks, K. and R.W. Leid. Arachidonic acid metabolism in caprine alveolar macrophages. *Inflammation* 14: 239-245, 1990
40. Englen, M.D., Taylor, S.M., Laegreid, W.W., Silflow, R.M. and R.W. Leid. Effects of different silicas on arachidonate metabolism in alveolar macrophages. *Exp. Lung Res.* 16: 691-709, 1990
41. Heidel, J.R., Taylor, S.M., Silflow, R.M. and R.W. Leid. Characterisation of arachidonic acid metabolism, superoxide production and bacterial killing by bovine alveolar neutrophils elicited with LTB₄ and zymosan activated plasma. *Inflammation* 1991, 15: 31-42
42. Silflow, R.M., Taylor, S.M., Laegreid, W.W., Liggitt, H.D. and R.W. Leid. Comparison of arachidonic acid metabolism by alveolar macrophages in bighorn and domestic sheep. *Inflammation* 14: 43-54, 1991
43. Englen, M.D., Taylor, S.M., Laegreid, W.W., Silflow, R. M. and R.W. Leid. Diminished arachidonic acid release by bovine alveolar macrophages exposed to surface-modified silica. *Am. J. Respir. Cell Mol. Biol.* 6: 527-534, 1992
44. Ember, J.A., Sanderson, S. D., Taylor, S.M., Kawahara, M., and T.E. Hugli. Biologic activity of synthetic analogs of C5a anaphylatoxin. *J. Immunol.* 148: 3165-3173, 1992
45. Taylor, S.M., Heron, A.E., Cannell, G.R. and T.H. Florin. Pressor effect of ethanol in the isolated, perfused human placental lobule. *Eur. J. Pharmacol.* 270: 371-374, 1994
46. Taylor, S.M., Finch, A.M., Heron, A.E., Brown, L.C. and T.H. Florin. Reversibility of tachyphylaxis to C5a in guinea-pig tissues, the perfused human placental lobule and the umbilical artery. *Inflammation* 18: 645-657, 1994
47. Sanderson, S.D., Ember, J.A., Kimarsky, L., Sherman, S.A, Finch, A. M and S.M. Taylor. Decapeptide agonists of human C5a: The relationship between

- conformation and spasmogenic and platelet aggregatory activities. *J. Med. Chem.* 37: 3171-3180, 1994
48. Shiels, I.A., Bowler, S.D. and S.M. Taylor. Airway smooth muscle proliferation in asthma: the potential of vascular leakage to contribute to pathogenesis. *Med. Hypotheses*. 45: 37-40, 1995
 49. Finch, AM, Heron AE, Tolhurst SL, Florin, TH, Sanderson SD & SM Taylor. The effect of C5a and U46619 on the isolated, perfused human placental lobule: development of a method for the on-line estimation of tissue fluid accumulation *J. Pharmacol Toxicol Methods*. 34: 133-141, 1995
 50. Sanderson SD, Kimarsky L, Sherman S, Ember JA, Finch AM & S M Taylor. Decapeptide agonists of human C5a: the relationship between conformation and neutrophil response, *J. Med. Chem.* 38: 3669-3675, 1995
 51. Shiels IA, Bowler, SD and SM Taylor. Homologous serum increases fibronectin expression and cell adhesion in airway smooth muscle cells. *Inflammation* 20: 373-388, 1996 7
 52. Kawatsu, R, Sanderson, SD, Blance, I, Kendall, N, Finch, AM, Taylor, SM and D. Colcher. Conformationally biased analogues of human C5a mediate changes in vascular permeability. *J. Pharmacol. Exp. Therap.* 278: 432-440, 1996 11
 53. Finch, AM, Vogen, SM, Sherman, SA, Kimarsky, L, Taylor, SM and SD Sanderson. A biologically active conformer of the effector region of human C5a and the modulatory effects of N-terminal receptor binding determinants on activity. *J. Med Chem.* 40: 877-884, 1997 22
 54. Tempero, RM, Hollingsworth, MA, Burdick, MD, Finch, AM, Taylor SM, Vogen SM, Morgan EL and Sanderson, SD Molecular adjuvant effects of a conformationally biased agonist of human C5a anaphylatoxin *J. Immunol.* 158: 1377-1382, 1997 15
 55. Shiels, IA, Zhang, S, Ambler, J and SM Taylor. Homologous serum induces phenotypic change and fibronectin expression in cultured retinal epithelial cells *Med. Hypotheses*. 50: 113-117, 1998. 6
 56. Wong, AK, Finch, AM, Pierons, G, Taylor, SM and Fairlie, DP. Molecular probes for G-protein coupled receptors. Conformationally constrained antagonists derived from the C-terminus of human plasma protein C5a. *J. Med. Chem.* 41: 3417-3425, 1998 20
 57. Zhang, S., I. A. Shiels, J. Ambler and S. M. Taylor. Pirfenidone reduces fibronectin synthesis by cultured human RPE cells. *Aust. N. Z. J. Ophthalmol.* 26, 574-576, 1998. 5
 58. Vogen, SM, Finch, AM, Wadi, K, Thatcher, J, Monk, PN, SM Taylor & Sanderson, SD. The role of the amino terminal end of decapeptide agonists of C5a in receptor binding and activation: Nature of the interaction of position 68 of C5a and Glu199 of the C5a receptor. *Peptide Res.* 53: 8-17, 1999
 59. Shiels, IA, SD Sanderson & SM Taylor. A multi-species, arterially-perfused eye model of uveitis to test a novel anti-inflammatory agent, pirfenidone. *Aust. Vet. J.* 77: 100-104, 1999.

- 60 Short, A, Wong, AK, Finch, AM, Haaima, G, Shiels, IA, Fairlie, DP & SM Taylor. Effects of a new C5a receptor antagonist on C5a- and endotoxin-induced neutropenia in the rat. *Br. J. Pharmacol.* 126: 551-554, 1999 25
- 61 Paczkowski NJ, Finch, AM, Whitmore, J, Short, AJ, Wong, AK, Monk, PN, Cain SA, Fairlie, DP and SM Taylor Pharmacological characterisation of antagonists of the C5a receptor *Br J Pharmacol* 128: 1461-1466, 1999. 30
- 62 Finch, AM, Wong, AK, Paczkowski, NJ, Wadi, SK, Craik, D, Fairlie, DP and S. M. Taylor. Low molecular weight peptidic and cyclic antagonists of the C5a receptor *J. Med Chem.* 42: 1965-1974, 1999 34
- 63 Wong, A.K.; Taylor, S. M.; Fairlie, D. P. Development of C5a receptor antagonists *Investigational Drugs* 2: 686-693, 1999
- 64 Shiels, IA, Bowler SD and SM Taylor The effects of salbutamol, beclomethasone and dexamethasone on growth and fibronectin expression by cultured airway smooth muscle cells. *Inflammation* 23: 321-331, 1999 8
- 65 Short, AJ, Paczkowski, NJ, Vogen, SM, Sanderson SD and S M Taylor. Response-selective C5a agonists: differential effects on neutropenia and hypotension in the rat. *Br. J. Pharmacol.* 128: 511-514, 1999. 10
- 66 Zhang, S, Shiels IA & SM Taylor. Homologous serum stimulated fibronectin synthesis in human retinal pigmented epithelial cells. *Aust. N. Z. J. Ophthalmol* 27: 247-249, 1999
- 67 Vogen SM, Finch AM, Wadi SK, Thatcher J, Monk PN, Taylor SM, Sanderson SD The influence of Lys68 in decapeptide agonists of C5a on C5a receptor binding, activation and selectivity *J Peptide Res.* 53: 8-17 1999 9
- 68 Shiels, IA, Taylor, SM and DP Fairlie. Targeting vascular leakage and structural change in chronic inflammatory diseases. *Med Hypotheses* 54: 193-197, 2000 3
- 69 Ulrich, JT, Cieplak, W, Paczkowski NJ, Taylor SM and SD Sanderson. Induction of an antigen-specific CTL immune response by a conformationally biased agonist of human C5a anaphylatoxin as a molecular adjuvant *J. Immunol.* 164: 5492-5498, 2000 5
- 70 Haynes DR, Harkin, DJ, Bignold, LP, Hutchens, M, Taylor, SM. & DP Fairlie. Inhibition of C5a-induced neutrophil chemotaxis and macrophage cytokine production *in vitro* by a new C5a receptor antagonist. *Biochem. Pharmacol.* 60: 729-733, 2000 17
- 71 Strachan, AJ, Woodruff, TM Haaima, G, Fairlie, DP and SM Taylor The role of the complement system in ischemia-reperfusion injury. Inhibition of the reverse passive Arthus reaction and endotoxic shock in rats by a small molecule C5a receptor antagonist. *J. Immunol.* 164: 6560-6565, 2000 34
- 72 Taylor, SM & DP Fairlie. Regulators of the anaphylatoxin C5a. *Expert Opinion in Therapeutic Patents.* 10: 449-458, 2000 3
- 73 Shiels IA, Taylor SM, Fairlie DP Cell phenotype as a target of drug therapy in chronic inflammatory diseases *Med Hypotheses* 54 : 193-197, 2000 3

- 74 Woodruff TM, AJ Strachan, SD Sanderson, P N Monk, AK Wong,[†] DP Fairlie and S M Taylor. Species variance in the binding affinity of new low molecular weight antagonists and agonists of the C5a receptor *Inflammation*, 25 :171-177, 2001 9
- 75 Cain S. A.; Woodruff, T. M.; Taylor, S. M.; Fairlie, D. P.; Monk, P. N. Mutations in the first extracellular loop of the human C5a receptor differentially affect responses to agonists and antagonists *Biochem. Pharmacol.* 61:1571-9, 2001 6
- 76 Stocks, SZ, Taylor, SM and I.A. Shiels. TGF- β , induced α -smooth muscle actin expression and fibronectin synthesis in cultured human retinal pigment epithelial cells *Clin Experiment Ophthalmol.* 29:33-7, 2001 3
- 77 Taylor SM, Sherman SA, Kimarsky L and SD Sanderson Development of response-selective agonists of human C5a anaphylatoxin: conformational, biological, and therapeutic considerations. *Curr Med Chem* 8:675-84, 2001 3
- 78 Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. *Br J Pharmacol.* ;133:687-94, 2001. 18
- 79 Strachan, AJ, IA Shiels, RC Reid, DP Fairlie, SM Taylor Inhibition of immune-complex mediated dermal inflammation following either oral or topical administration of a small molecule C5a receptor antagonist. *Br J Pharmacol* 134: 1778-1786, 2001 14
- 80 Vogen SM, Paczkowski NJ, Kimarsky L, Short A, Whitmore JB, Sherman SA, Taylor SM, Sanderson SD. Differential activities of decapeptide agonists of human C5a: the conformational effects of backbone N-methylation. *Int Immunopharmacol.* 1:2151-62, 2001.
- 81 Mirkovic S, AL Seymour, A Fenning, A Strachan, S B Margolin, S M Taylor and L Brown Selective reversal of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats *Br J Pharmacol* 135; 961-968, 2002 7
- 82 Arumugam TV, IA Shiels, S B Margolin, SM Taylor and L Brown Pirfenidone attenuates ischaemia-reperfusion injury in the rat small intestine *Clin. Exp. Physiol. Pharmacol.* 29; 996-1000, 2002 1
- 83 Arumugam, TV, IA. Shiels, TM. Woodruff, RC Reid, DP. Fairlie and SM. Taylor. A small molecule C5a receptor antagonist protects the rat small intestine against ischemia-reperfusion injury. *J. Surg. Res.* 103: 260-267, 2002 16
- 84 Woodruff TM, Strachan AJ, Dryburgh, N, Shiels IA, Reid RC, DP. Fairlie, and SM Taylor Anti-arthritis activity of an orally active C5a receptor antagonist against antigen-induced monoarticular arthritis in the rat. *Arthritis and Rheumatism* 46: 2476-2485, 2002 6
- 85 ArumugamTV, Shiels IA, Strachan AJ, Abbenanate G, Fairlie DP and SM. Taylor A small molecule C5a receptor antagonist protects kidneys against ischemia-reperfusion injury in rats. *Kidney International* 63:134-42, 2003

- 86 Harkin, DW, BB Rubin, SM Taylor, AD Romaschin, TF Lindsay Complement C5a Receptor Antagonist Attenuates Multiple Organ Injury in a Model of Ruptured Abdominal Aortic Aneurysm *J. Vasc. Surg.* 39: 196-206, 2004
- 87 Arumugam, T, Arnold, N, Newman, M, Reid, RC, Hansford, K, Fairlie, DP, Shiels, IA and SM Taylor. Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA₂, COX-1 and COX-2 selective inhibitors, and an LTC₄ receptor antagonist. *Br J Pharmacol.* 140:71-80, 2003
- 88 Woodruff TM, Arumugam, T, Shiels IA, Reid RC, DP, Fairlie, and SM Taylor A potent C5a receptor antagonist inhibits markers of local and remote organ injury following tourniquet-induced limb ischemia-reperfusion in rats. *J. Surg. Res.* 116: 81-90, 2004
- 89 Woodruff, T. M.; Arumugam, T. V.; Shiels, I. A.; Reid, R. C.; Fairlie, D. P.; Taylor, S. M. A Potent C5a Receptor Antagonist Inhibits and Reverses Disease Pathology in a Rat Model of Inflammatory Bowel Disease, *J. Immunol.* 171: 5514-5520, 2003.
- 90 Reid, RC, Abbenante, G, Taylor, SM and DP Fairlie A Convergent Solution Phase Synthesis of the Macrocyclic, Ac-Phe-[Orn-Pro-D-Cha-Trp-Arg], a Potent New Anti-Inflammatory Drug *J. Org. Chem.* 68: 4464-71, 2003
- 91 Proctor, LM, Arumugam, TV, Shiels, IA, Woodruff, TM, Reid, RC, Fairlie, DP and SM Taylor Comparative Anti-inflammatory Activities of Antagonists to C3a and C5a Receptors in a Rat Model of Intestinal Ischaemia/Reperfusion Injury *Br J Pharmacol* Accepted for Publication 2004
- 92 Arumugam, TV, IA Shiels, TM Woodruff, DN Granger and SM Taylor The role of the complement system in ischemia-reperfusion injury: a review *Shock* 21:401-409, 2004
- 93 Arumugam, TV, TM Woodruff, LM Proctor, S Pollitt, SZ Stocks, IA Shiels, RC Reid, DP Fairlie and SM Taylor. Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats *J. Hepatol.* In Press 2004
- 94 Arumugam TV, TM Woodruff, LM Proctor, KA Hansford, C Reid, IA Shiels, DP Fairlie and SM Taylor Beneficial effects of a new sPLA₂ inhibitor and C5a receptor antagonist against cold storage-induced ischaemic liver and renal injury in UW solution Submitted
- 95 March, DR, LM Proctor, MJ Stoermer, R Sbaglia, G Abbenante, RC Reid, K Wadi, JD Tyndall, SM Taylor, and DP Fairlie. Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Structure-activity relationships *Mol. Pharmacol.* 65:868-79, 2004

- 96 Woodruff, TM, N Dryburgh, RC. Reid, KA. Hansford, DP. Fairlie, SM. Taylor and IA. Shiels Anti-Inflammatory Properties of an Orally Active Secretory Phospholipase A₂ Inhibitor in Antigen-Induced Monoarticular Arthritis in the Rat. Submitted
- 97 Cain, SA, Taylor, SM, Proctor LM, Fairlie, DP and PN Monk The effects of mutating putative activation switch residues on the activity of a cyclic peptide C5a receptor antagonist Submitted
- 98 Shiels, IA, M Pappas, R Reid, DP Fairlie, SM Taylor. An inhibitor of the secretory phospholipase A₂ enzyme reduces contractions in rat uterus. Submitted
- 99 Proctor, LM, Woodruff, TM, Packowski, NJ, Strachan, AJ, Monk, PM, Reid, RC, Ross, PA, Fairlie DP and SM Taylor. Peptide Analogues of the C-terminus of C3a and C5a have Differential Hemodynamic Effects in the Rat Submitted.
- 100 Woodruff, TM, TV Arumugam, IA. Shiels, M L Newman, RC Reid, DP Fairlie, and SM Taylor. A Potent and Selective Inhibitor of Group IIa Secretory Phospholipase A₂ Protects Rats From TNBS-Induced Colitis submitted

Book Chapters

Taylor SM & DP Fairlie Discovery of Potent Cyclic Antagonists of Human C5a Receptors. In: Structural Biology of the Complement System. 2004 Eds. J Lambris and D Morikis Marcel Dekker NY USA.

Patents

- 1 Sanderson SD, Kirnarsky L, Sherman S, & SM Taylor. High affinity response-selective C-terminal analogs of C5a. *U.S. Patent 5,942,599* Issued 24/8/1999
- 2) Taylor, S. M.; Fairlie, D. P. "Cyclic Agonists and Antagonists of C5a Receptors and G Protein-Coupled Receptors" Aust. Patent 744991, 25 June 1997. International Patent PCT/AU98/00490, Filed 25 June 1998.
- 3) Shiels, I.; Taylor, S.M.; Fairlie, D. P. "A new method for the treatment of dysmenorrhoea and menstrual side effects : the use of inhibitors of human secretory phospholipases A₂" filed as "Compositions and methods of using them" Aust. Provisional Patent, filed 14 July, 2000, PQ8764/00. *International Patent Application* 2004, PCT/AU01/00858
- 4) Taylor SM, Shiels IA and Brown LC. Use of C5a Receptor Antagonist in the Treatment of Fibrosis. *International Patent PCT/AU03/00415, Filed 8 April 2004.*

- 5) Taylor SM, Shiels IA, Fairlie DP. G Protein-Coupled. Receptor Antagonists. *International Patent PCT/AU02/01427, Filed 17 October 2002*
- 6) Woodruff TM and Taylor SM. Treatment of Inflammatory Bowel Disease. *International Patent PCT/AU2003/001365, Filed 17 October 2002.*
- 7) Taylor, S. M., Shiels, I.A Treatment of osteoarthritis by C5a antagonists. International Patent PCT/AU2003/001373, Filed 17 October 2002.
- 8) Shiels IA, Taylor SM and Fairlie D. Treatment of Hypersensitivity Conditions. *International Patent PCT/AU2003/001374, Filed 17 October 2002.*
- 9) Lindsay T, Harkin D and Taylor SM. Treatment of Haemorrhagic Shock. *Australian Patent Application No 2003902354, Filed 15 May 2003.*
- 10) Taylor SM and Shiels IA. Treatment of Burns. *Australian Patent Application No 2003902586, Filed 26 May 2003.*
- 11) Woodruff TM, Shiels IA and Taylor SM Treatment of neurological conditions. *Australian Provisional Patent Application , Filed April 2004.*